![]() |
|
|
Vol. 60, Issue 1, 63-70, July 2001
-Arrestin I, and Endocytic
Processing
Department of Physiology and Pharmacology, Strathclyde Institute for Biomedical Sciences, University of Strathclyde, Glasgow, Scotland, United Kingdom
| |
Abstract |
|---|
|
|
|---|
In this study, we have shown that nerve growth factor (NGF)-dependent
activation of the p42/p44 mitogen-activated protein kinase (p42/p44
MAPK) pathway in PC12 cells can be partially blocked by pertussis toxin
(which inactivates the G proteins Gi/o). This suggests that
the Trk A receptor may use a G protein-coupled receptor pathway to
signal to p42/p44 MAPK. This was supported by data showing that the
NGF-dependent activation of p42/p44 MAPK is potentiated in cells
transfected with G protein-coupled receptor kinase 2 (GRK2) or
-arrestin I. Moreover, GRK2 is constitutively bound with the Trk A
receptor, whereas NGF stimulates the pertussis toxin-sensitive binding
of
-arrestin I to the TrkA receptor-GRK2 complex. Both GRK2 and
-arrestin I are involved in clathrin-mediated endocytic signaling to
p42/p44 MAPK. Indeed, inhibitors of clathrin-mediated endocytosis
(e.g., monodansylcadaverine, concanavalin A, and hyperosmolar sucrose)
reduced the NGF-dependent activation of p42/p44 MAPK. Finally, we have
found that the G protein-coupled receptor-dependent component
regulating p42/p44 MAPK is required for NGF-induced differentiation of
PC12 cells. Thus, NGF-dependent inhibition of DNA synthesis was
partially blocked by PD098059 (inhibitor of MAPK kinase-1 activation)
and pertussis toxin. Our findings are the first to show that the Trk A
receptor uses a classic G protein-coupled receptor-signaling
pathway to promote differentiation of PC12 cells.
| |
Introduction |
|---|
|
|
|---|
Nerve
growth factor (NGF) promotes the survival and differentiation of
sensory and sympathetic neurons. NGF also induces growth arrest of PC12
cells, which then accumulate in the G1 phase of the cell cycle and subsequently undergo differentiation. NGF binds to a
specific high-affinity tyrosine kinase receptor, Trk A. Binding of NGF
to Trk A induces autophosphorylation of the receptor on specific
tyrosine residues. The subsequently phosphorylated sites on the
receptor act as acceptors for the recruitment and assembly of signaling
complexes, such as Grb-2, phospholipase C
, and PI3K to elicit
intracellular responses. For instance, the binding of the SH2
containing protein Shc, Grb-2, and mSos site to phospho-Tyr-490 on the
Trk A receptor elicits Ras-dependent activation of the p42/p44 MAPK pathway.
The novel neuronal substrate FRS2 also uses the same docking site on
the Trk A receptor as the SH2-containing protein Shc and has been
implicated in the stimulation of the Ras-dependent p42/p44 MAPK pathway
by forming a complex with the tyrosine phosphatase SHP-2, and
associated adaptor proteins Grb-2, mSos, and Crk. This is achieved via
its association with C3G and leads to the sustained activation of the
small G protein Rap1. Rap1 then complexes to and activates B-raf,
resulting in subsequent downstream stimulation of the p42/p44 MAPK
pathway (York et al., 1998
). Because NGF activates Ras and c-Raf
transiently and B-Raf in a sustained manner, the prevalent view is that
transient activation of p42/p44 MAPK leads to cell proliferation,
whereas a more prolonged activation of this kinase pathway by NGF
promotes cell differentiation (Marshall, 1995
; Tombes et al., 1998
).
Recent studies have shown that the insulin-like growth factor-1 (IGF-1)
can use the G proteins, Gi/o to stimulate
activation of p42/p44 MAPK in fibroblasts (Luttrell et al. 1995
). This
was established using pertussis toxin (which inactivates
Gi/o) and the C-terminal domain of
-adrenergic
kinase (which sequesters G
subunits). Both
reduced the IGF-1-dependent activation of p42/p44 MAPK. These agents
also reduced fibroblast growth factor-dependent activation of p42/p44
MAPK in fibroblasts and promoted differentiation (Fedorov et al. 1998
).
Recent studies have also implicated the involvement of G
protein-coupled receptor kinase 2 (GRK2) and
-arrestin I and II in
regulating IGF-1- and
-adrenergic receptor-stimulated p42/p44 MAPK
activation via a process that involves clathrin-mediated endocytosis of
receptor-signal complexes (Daaka et al. 1998
; Ahn et al. 1999
; Lin et
al. 1999
). GRK2 is activated in an agonist- and G protein-dependent
manner.
-arrestin I/II are clathrin adaptor proteins that promote
dynamin II-mediated internalization of receptor signal complexes
containing c-Raf-MAPK kinase-1 for subsequent activation of p42/p44
MAPK.
Certain G protein-coupled receptor agonists have also been shown to
stimulate the tyrosine phosphorylation/trans-activation of
growth factor receptors. The subsequently phosphorylated sites on the
receptor act as acceptors for the recruitment and assembly of signaling
complexes such as Grb-2, phospholipase C
, and PI3K to elicit
mitogenic responses. For instance, LPA has been shown to
trans-activate the EGF receptor and
p185neu to stimulate p42/p44 MAPK activation in
Cos-7 cells (Daub et al., 1996
), whereas angiotensin II can induce
platelet-derived growth factor (PDGF) receptor
trans-activation in vascular smooth muscle (Linsemen et al.
1995
).
We have shown that the PDGF can also use
Gi-dependent and -independent routes to promote
stimulation of c-Src and p42/p44 MAPK in cultured airway smooth muscle
cells (Conway et al. 1999
; Rakhit et al. 2000
). Furthermore, c-Src
inhibitors abolished the PDGF-dependent activation of p42/p44 MAPK in
these cells. We have suggested that Gi might
recruit c-Src near the PDGF receptor tyrosine kinase for activation.
Furthermore, PDGF stimulates a Gi-mediated tyrosine phosphorylation of the Grb-2 associated binding protein, Gab1.
This promotes the binding of tyrosine-phosphorylated PI3K1a to Gab1 and
is required for dynamin II mediated endocytic stimulation of the
p42/p44 MAPK pathway (Rakhit et al. 2000
). Moreover, Gab1 binds to and
activates PI3K (Kaplan and Millar, 1997
; Korhonen et al., 1999
) in
response to NGF in neuronal cells. This raises the possibility that the
Trk A receptor may also use classic GPCR-dependent signaling to
regulate activation of the p42/p44 MAPK pathway. However, to date there
is no direct evidence to support this proposed model.
Therefore, in this article, we have investigated whether the NGF-dependent activation of p42/p44 MAPK involves a classic GPCR signaling pathway. We have also evaluated whether this pathway has an important role in regulating the differentiation of PC12 cells.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
All biochemicals, including NGF, were from Sigma
Chemical Co. (Dorset, UK). [3H]Thymidine,
[
-32P]ATP (3000 Ci/mol), MAPK Biotrak assay
kits, and enhanced chemiluminescence reagents were from Amersham
Pharmacia Biotech (Bucks, UK). Cell culture supplies were from Life
Technologies (Paisley, UK). Anti-phospho-p42/p44 MAPK antibodies were
from New England Biolabs (Beverly, MA). Anti-p42/p44 MAPK and
HRP-linked anti-phosphotyrosine antibodies were from Transduction
Laboratories (Lexington, KY). Anti-Trk A phospho-Tyr-490 and Trk A
antibodies were from New England Biolabs (Beverly, MA). Anti-FLAG
antibody was from Stratagene (La Jolla, CA). Anti-
-arrestin I
antibody was from Santa Cruz Biotechnology (Santa Cruz, CA). Reporter
HRP-anti-mouse/rabbit antibodies were from the Scottish Antibody
Production Unit (Carluke, Scotland). pRK5-GRK2 and pcDNA3-
arr1 FLAG
cDNA plasmid constructs and anti-GRK2 antibodies were kind gifts
from Professor R. Lefkowitz (Duke University, Durham, NC).
Cell Culture. PC12 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal calf serum (FCS). Cells were placed in DMEM supplemented with 0.1% (v/v) fetal calf serum (FCS) for 24 h before experimentation. In some cases, pertussis toxin (0.1 µg/ml) was added to the DMEM supplemented with 0.1% (v/v) FCS.
Transfection.
PC12 cells were transiently transfected with
-arrestin I or GRK2 plasmid constructs. Cells at 90% confluence
were placed in DMEM containing 2% (v/v) FCS and transfected with 2 to
4 µg of plasmid construct after complex formation with LipofectAMINE 2000, according to the Manufacturer's instructions. The cDNA
containing media was then removed after 24 h at 37°C, and the
cells incubated for a further 24 h in DMEM supplemented with 0.1%
(v/v) FCS before addition of agonists.
p42/p44 MAPK Assays.
The phosphorylation and activation of
p42/p44 MAPK was detected by Western blotting using an
anti-phospho-p42/p44 MAPK antibody. p42/p44 MAPK activity was also
measured in PC12 cell lysates using a specific p42/p44 MAPK peptide
substrate (EGFR661-680 peptide synthesized to
contain one phosphorylation site) as we described previously (Conway et
al. 1999
).
Blotting.
Immunoblotting was performed as we described
previously (Conway et al., 1999
; Rakhit et al. 1999
). Briefly,
nitrocellulose membranes were blocked for 2 h at 4°C in 10 mM
phosphate-buffered saline and 0.1% (v/v) Tween-20 containing 5% (w/v)
nonfat dried milk and 0.001% (w/v) thimerosal. The nitrocellulose
sheets were then incubated overnight at 4°C in blocking solution
containing antibodies. The sheets were then washed with
phosphate-buffered saline and 0.1% (v/v) Tween-20 before incubation
with HRP-linked anti-rabbit mouse antibodies in blocking solution for
2 h at room temperature. In the case of HRP-linked
anti-phosphotyrosine antibodies, no secondary antibody was used. After
washing the blots as above, immunoreactive proteins were visualized
using the enhanced chemiluminescence detection kit and were quantified
using densitometry.
Immunoprecipitation of Trk A.
The medium was removed and
cells lysed in ice-cold immunoprecipitation buffer (1 ml) containing 20 mM Tris-HCl, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2,
1 mM CaCl2, 1% (v/v) Nonidet P-40 (NP-40), 10%
(v/v) glycerol, 1 mg/ml bovine serum albumin, 0.5 mM sodium orthovanadate, 0.2 mM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, antipain, pepstatin, and aprotinin; pH 8) for 10 min at
4°C. The material was harvested, centrifuged at 22,000g
for 5 min at 4°C and 200 µl of cell lysate supernatant (equalized for protein, 0.5 to 1 mg/ml) taken for immunoprecipitation with antibodies (5 µg of anti-Trk A-490 phosphotyrosine or Trk A
antibodies and 30 µl of 1 part immunoprecipitation buffer and 1 part
protein A Sepharose CL4B, pre-equilibrated with lysis buffer. After
agitation for 2 h at 4°C, the immune complex was collected by
centrifugation at 22,000g for 15 s at 4°C.
Immunoprecipitates were washed twice with buffer A [containing 10 mM
HEPES, pH 7, 100 mM NaCl, 0.2 mM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, 20 µg/ml aprotinin, and 0.5% (v/v) NP-40] and
once in buffer A without NP-40. Samples were taken for Western blotting
with HRP-linked anti-phosphotyrosine or anti-GRK2 or
-arrestin I
antibodies
DNA Synthesis.
[3H]Thymidine
incorporation studies were performed as described by Rakhit et al.
(1999)
.
cAMP Assays. Intracellular cAMP was measured using a cAMP enzyme-linked immunosorbent assay kit as described by the manufacturer (Amersham Pharmacia Biotech).
| |
Results |
|---|
|
|
|---|
The NGF-Dependent Activation of p42/p44 MAPK.
The treatment of
PC12 cells with NGF stimulated p42/p44 MAPK activation in a
dose-dependent manner (Fig. 1A). p42/p44
MAPK was activated ~5- to 6-fold above basal using a maximal
concentration of 50 ng/ml NGF, measured using a specific p42/p44 MAPK
peptide (EGFR661-680 peptide substrate assay)
(Fig. 1B). Using 5 ng/ml NGF, the activation of p42/p44 MAPK was
sustained for at least 30 min (Fig. 1C). The inhibitor of MAP kinase-1
activation, PD098059 markedly reduced the NGF-dependent activation of
p42/p44 MAPK (Fig. 1D).
|
NGF Uses a Classic GPCR-Mediated Pathway to Stimulate the p42/p44 MAPK Pathway The treatment of PC12 cells with the bacterial toxin, pertussis toxin (which inactivates the G proteins Gi/o) at 0.1 µg/ml for 24 h reduced the NGF-dependent activation of p42/p44 MAPK by ~80% at a low concentration of NGF (5 ng/ml) (Fig. 1A). In contrast, only p42 MAPK activation was reduced by pertussis toxin at a high concentration of NGF (50 ng/ml) (Fig. 1A).
Pertussis toxin also seems to have a more profound effect during the early phase activation of p42/ MAPK (0-5 min) at low concentrations of NGF (5 ng/ml). The effect of pertussis toxin diminished after 10-min stimulation, whereas after 30 min, no effect was observed (Fig. 1C). Pertussis toxin had no effect on the expression level of p42 MAPK (Fig. 1, A and C). The specificity and action of pertussis toxin in inactivating Gi/o-mediated signaling was further characterized using lysophosphatidate, which binds to a Gi-coupled receptor, and EGF, which does not use these G proteins. Figure 1E shows that the LPA-dependent stimulation of p42/p44 MAPK was markedly reduced by pretreating cells with pertussis toxin, whereas the response to EGF was unaffected. Under the conditions used in these experiments, pertussis toxin partially inactivated Gi. This was evidenced from experiments showing that the LPA-induced reduction in basal cAMP levels was partially blocked by the toxin (Fig. 2).
|
|
-adrenoceptor antagonist), and yohimbine
(
2-adrenoceptor antagonist) have no effect on
the activation of p42/p44 MAPK by NGF (Fig.
4).
|
Tyrosine Phosphorylation of the Trk A Receptor.
We next
investigated whether the Trk A receptor uses Gi/o
to promote phosphorylation of tyrosine sites on the receptor. This would enable the recruitment of signal complexes to the receptor, thereby initiating stimulation of the p42/p44 MAPK pathway. To evaluate
this, we assessed the effect of pertussis toxin on NGF-stimulated phosphorylation of Tyr-490 in the Trk A receptor. Tyr-490 is the relevant phosphorylation site because it functions as an adaptor site
for Grb2/mSos complex as well as FRS2, both of which are required for
activation of the p42/p44 MAPK pathway. The pretreatment of PC12 cells
with pertussis toxin had no effect on NGF-stimulated Tyr-490
phosphorylation, which was detected in anti-Trk A phospho-Tyr-490 immunoprecipitates with HRP-linked anti-phosphotyrosine antibodies (Fig. 5). The tyrosine-phosphorylated
protein (molecular mass, 140 kDa) was also immunostained with specific
anti-Trk A antibody (equal amounts of the protein were
immunopreciptated from each sample) (data not shown).
|
Role of PI3K.
Certain G protein-coupled receptor agonists use
a PI3K-dependent pathway to stimulate p42/p44 MAPK in mammalian cells.
Moreover, several growth factor receptors that regulate p42/p44 MAPK
activation via a Gi/o-dependent mechanism also
seem to require PI3K (Rakhit et al., 2000
). Consistent with these
findings, we show here that the NGF (5 ng/ml)-dependent stimulation of
p42/p44 MAPK has a mandatory requirement for PI3K, because the
stimulation of p42/p44 MAPK was reduced by ~70% by pretreating PC12
cells with the PI3K inhibitor wortmannin (Fig.
6).
|
The Effect of GRK2 and
-Arrestin I on the NGF-Dependent
Activation of p42/p44 MAPK.
We next investigated whether
transfecting cells with GRK2 and
-arrestin I can increase the
NGF-dependent activation of p42/p44 MAPK. These proteins play a key
role in regulating p42/p44 MAPK activation in response to G
protein-coupled receptors (Daaka et al. 1998
; Ahn et al. 1999
; Lin et
al. 1999
).
-arrestin I
(molecular mass, 55 kDa) in PC12 cells transfected with respective
plasmid constructs and detected with anti-FLAG and GRK2 antibodies.
FLAG-
-arrestin I was not detected in vector-transfected cells.
Figure 7A, bottom, shows that the NGF-dependent activation of p42/p44
MAPK was potentiated ~3- to 5-fold in cells overexpressing either
GRK2 or
-arrestin I. This stimulation was not further enhanced when
cells were cotransfected with both proteins compared with either alone.
|
-arrestin I participate in
Trk A signaling. However, to establish a role for the endogenous forms,
it was also necessary to show that these proteins are expressed in PC12
cells and that they form a complex with the Trk A receptor. Figure 7b
shows that GRK2 and
-arrestin I are expressed in PC 12 cells and can
be immunostained in cells lysates that have been Western blotted with
anti-GRK2 and
-arrestin I antibodies, respectively. Furthermore,
both endogenous and recombinant GRK2 are constitutive bound in a
complex with the Trk A receptor in these cells (Fig. 7B, top). Low but
detectable levels of endogenous GRK2 were found associated with the Trk
A receptor; this was increased in GRK2-transfected cells. GRK2 was
detected in anti-Trk A receptor immunoprecipitates by Western blotting
with anti-GRK2 antibodies. In Fig. 7B, bottom, we show that NGF
stimulates the binding of endogenous and recombinant
-arrestin I to
the Trk A receptor-GRK2 complex, which is prevented by pretreating
cells with pertussis toxin. Endogenous
-arrestin I was detected in
anti-Trk A receptor immunoprecipitates by Western blotting with
anti-
-arrestin I antibodies, whereas recombinant
-arrestin I was
detected with anti-FLAG antibodies. In all cases, the
immunoprecipitation of Trk A was not altered by the various treatments
(data not shown).
The Effects of Inhibitors of Clathrin Mediated Receptor
Endocytosis.
Recent studies have confirmed that certain G
protein-coupled receptor agonists use
-arrestin I as a clathrin
adaptor to mediate endocytosis of receptor signal complexes (which
include c-Raf-MAPK kinase-1) to trigger activation of p42/p44 MAPK.
PC12 cells were therefore preincubated with the inhibitors of
clathrin-mediated endocytosis, such as concanavalin A (which prevents
receptor clustering), hyperosmolar sucrose (which blocks clathrin
association), and monodansylcadaverine (MDC) to establish their effect
on NGF-stimulated p42/p44 MAPK activation. Figure
8a shows that concanavalin A and hyperosmolar sucrose markedly reduced the NGF-dependent activation of
p42/p44 MAPK (~80-90% inhibition). Figure 8B shows the
concentration-dependent inhibition of the NGF-dependent stimulation of
p42/p44 MAPK by MDC.
|
The Effect of NGF on DNA Synthesis.
We next investigated
whether the G protein-coupled receptor-dependent component regulating
p42/p44 MAPK is required for NGF-induced differentiation of PC12 cells.
The data is shown in Fig. 9. First, we
found that NGF induces a marked reduction in
[3H]thymidine incorporation into DNA. This was
dose-dependent with maximal inhibition at 10 to 50 ng/ml NGF (Fig. 9A).
Pretreatment of cells with PD098059 or pertussis toxin at
concentrations that reduced the NGF-dependent stimulation of p42/p44
MAPK activation blocked the NGF-induced inhibition of DNA synthesis
(Fig. 9, B and C). In both cases, DNA synthesis was not completely
restored to the basal level (~50-60% of basal level).
Significantly, inhibition of DNA synthesis was also observed in
response to LPA, thereby confirming that G protein-coupled receptor
agonists can indeed induce growth arrest of PC12 cells (Fig. 9C).
|
| |
Discussion |
|---|
|
|
|---|
We have reported that the pretreatment of PC12 cells with
pertussis toxin (which inactivates the G proteins
Gi/o) reduces the NGF-dependent activation of
p42/p44 MAPK. Because pertussis toxin was without effect on the
NGF-stimulated phosphorylation of Tyr-490 in the Trk A receptor, we
suggest that the Trk A receptor can use Gi/o as
coupling proteins to regulate p42/p44 MAPK activation. The mechanism by
which the Trk A receptor interacts with Gi/o is
not known. However, other studies have reported that growth factor
receptors can interact with G proteins (Rothenberg and Kahn, 1988
;
Luttrell et al., 1990
). Recently, IGF-1 has been shown to activate
Gi to release 
subunits (Hallak et al.
2000
), which in turn initiates activation of the p42/p44 MAPK pathway
(Luttrell et al. 1995
).
Additional evidence showing that the Trk A receptor uses classic G
protein-coupled receptor signaling pathways was obtained using cells
transiently transfected with GRK2 or
-arrestin I. Both recombinant
proteins potentiated the NGF-dependent stimulation of p42/p44 MAPK.
Thus, endogenous GRK2 and
-arrestin I might also behave in a similar
manner. This was supported by the finding that both endogenous and
recombinant GRK2 are constitutively bound in a complex with the Trk A
receptor. Moreover, NGF stimulates a pertussis toxin-sensitive
association of
-arrestin I with the Trk A receptor-GRK2 complex.
This interaction is similar with the role of GRK2 in regulating G
protein-coupled receptor signaling processes, where it is activated by
G
and catalyzes the
phosphorylation of ligand bound G protein-coupled receptors, thus
creating a binding site for
-arrestin I/II. This leads to an
uncoupling of the receptor from its G protein, followed by rapid
receptor internalization and stimulation of p42/p44 MAPK.
A number of GPCR agonists and growth factor receptors that can use
Gi/o to stimulate p42/p44 MAPK do so via a
PI3K-dependent pathway in mammalian cells. Consistent with this, we
found that the NGF-dependent activation of p42/p44 MAPK was blocked by
~70% by pretreating cells with the PI3K inhibitor, wortmannin. Other growth factors (e.g., PDGF) stimulate a
Gi-mediated tyrosine phosphorylation of Gab1
required for binding of PI3K1a and subsequent dynamin II-mediated
stimulation of the p42/p44 MAPK pathway (Rakhit et al. 2000
). Moreover,
NGF also seems to stimulate the binding of PI3K to Gab1 (Kaplan and
Millar, 1997
; Korhonen et al., 1999
). This may be important in
regulating NGF-dependent endocytic signal processes in the cell.
Indeed, we show here that the NGF-dependent activation of p42/p44 MAPK
can be blocked by ~80% with endocytosis inhibitors.
An interesting finding in the current study was that at low
concentrations of NGF (5 ng/ml), pertussis toxin substantially reduced
the activation of p42/p44 MAPK, whereas at a high concentration of NGF
(50 ng/ml), only p42 MAPK activation was affected. Therefore, whereas
NGF seems to elicit a more robust activation of p42/p44 MAPK at high
receptor occupancy, the requirement of p44 MAPK activation for
Gi/o seems to be surmounted. Importantly, these
findings suggest that the two MAPK isoforms may be differentially
regulated at high Trk A occupancy. The ability of growth factors to
surmount the requirement of Gi/o has been
reported before [e.g., insulin (Luttrell et al. 1995
)]. These authors
found that insulin at low insulin receptor density stimulated p42/p44
MAPK activation in a pertussis toxin-sensitive manner in fibroblasts,
whereas at high insulin receptor density, insulin stimulated a more
robust activation of p42/p44 MAPK that was insensitive to pertussis toxin.
Finally, we have found that the GPCR-dependent component regulating p42/p44 MAPK in response to NGF is required for differentiation of PC12 cells. This was based on experiments showing that PD098059 (inhibitor of MAPK kinase-1 activation) and pertussis toxin partially blocked NGF-induced inhibition of DNA synthesis. Indeed, other agonists that use G protein-coupled receptor signaling pathways to regulate p42/p44 MAPK, such as LPA, also induce differentiation of PC12 cells. The fact that PD098059 and pertussis toxin did not fully restore DNA synthesis suggests that NGF may also use additional pathways to promote growth arrest.
In conclusion, our findings show for the first time that the Trk A
receptor can use Gi/o to promote efficient
activation of the p42/p44 MAPK pathway required for cell
differentiation. This seems to involve GRK2-
-arrestin-I and
endocytosis of Trk A receptor signal complexes. These findings are
novel and significant as they break the conventional paradigm for
growth factor receptor signaling and strengthen an emerging model that
such growth factor receptors can indeed, use classic GPCR signaling
pathway to stimulate p42/p44 MAPK.
| |
Footnotes |
|---|
Received August 25, 2000; Accepted February 9, 2001
This study was supported by grants from the Wellcome Trust and the Strathclyde University Research and Development fund. S.P. is a Wellcome Trust Senior Fellow.
Dr. N. J. Pyne, Department of Physiology and Pharmacology, Strathclyde Institute for Biomedical Sciences, University of Strathclyde, 27 Taylor St, Glasgow, G4 0NR Scotland, UK. E-mail: n.j.pyne{at}strath.ac.uk
| |
Abbreviations |
|---|
NGF, nerve growth factor; MAPK, mitogen-activated protein kinase; IGF, insulin-like growth factor; GRK, G protein-coupled receptor kinase; Grb-2, growth factor receptor binding protein; PI3K, phosphoinositide 3-kinase; LPA, lysophosphatidic acid; PDGF, platelet-derived growth factor; Gi, inhibitory G protein; Gab1, growth factor receptor binding protein associated binder; HRP, horseradish peroxidase; DMEM, Dulbecco's modified Eagle's medium; FCS, fetal calf serum; NP-40, Nonidet P-40; EGF, epidermal growth factor; GPCR, G protein-coupled receptor; mSos, son of sevenless; c-Src, cellular Src tyrosine kinase; MDC, monodansylcadaverine.
| |
References |
|---|
|
|
|---|

subunits upon receptor activation.
J Biol Chem
275:
2255-2258
-Arrestins regulate mitogenic signaling and clathrin-mediated endocytosis of the insulin-like growth factor I receptor.
J Biol Chem
273:
31640-31643
subunits mediate mitogen-activated protein kinase activation by the tyrosine kinase insulin-like growth factor 1 receptor.
J Biol Chem
270:
16495-16498This article has been cited by other articles:
![]() |
S. K. Shenoy and R. J. Lefkowitz Seven-Transmembrane Receptor Signaling Through {beta}-Arrestin Sci. Signal., November 1, 2005; 2005(308): cm10 - cm10. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Neve Double Feature at the Signalplex Mol. Pharmacol., August 1, 2005; 68(2): 275 - 278. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. H. T. Wu and Y. H. Wong Involvement of Gi/o Proteins in Nerve Growth Factor-Stimulated Phosphorylation and Degradation of Tuberin in PC-12 Cells and Cortical Neurons Mol. Pharmacol., April 1, 2005; 67(4): 1195 - 1205. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Toman, S. G. Payne, K. R. Watterson, M. Maceyka, N. H. Lee, S. Milstien, J. W. Bigbee, and S. Spiegel Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension J. Cell Biol., August 2, 2004; 166(3): 381 - 392. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ahamed, R. T. Venkatesha, E. B. Thangam, and H. Ali C3a Enhances Nerve Growth Factor-Induced NFAT Activation and Chemokine Production in a Human Mast Cell Line, HMC-1 J. Immunol., June 1, 2004; 172(11): 6961 - 6968. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Iacovelli, L. Capobianco, M. Iula, V. Di Giorgi Gerevini, A. Picascia, J. Blahos, D. Melchiorri, F. Nicoletti, and A. De Blasi Regulation of mGlu4 Metabotropic Glutamate Receptor Signaling by Type-2 G-Protein Coupled Receptor Kinase (GRK2) Mol. Pharmacol., May 1, 2004; 65(5): 1103 - 1110. [Abstract] [Full Text] |
||||
![]() |
A. M. Krumins, S. A. Barker, C. Huang, R. K. Sunahara, K. Yu, T. M. Wilkie, S. J. Gold, and S. M. Mumby Differentially Regulated Expression of Endogenous RGS4 and RGS7 J. Biol. Chem., January 23, 2004; 279(4): 2593 - 2599. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Peterson, M. R. Sutherland, M. E. Nesheim, and E. L. G. Pryzdial Thrombin induces endothelial cell-surface exposure of the plasminogen receptor annexin 2 J. Cell Sci., June 15, 2003; 116(12): 2399 - 2408. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. F. Wan, B. S. Sambi, R. Tate, C. Waters, and N. J. Pyne The Inhibitory gamma Subunit of the Type 6 Retinal cGMP Phosphodiesterase Functions to Link c-Src and G-protein-coupled Receptor Kinase 2 in a Signaling Unit That Regulates p42/p44 Mitogen-activated Protein Kinase by Epidermal Growth Factor J. Biol. Chem., May 9, 2003; 278(20): 18658 - 18663. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Waters, B. Sambi, K.-C. Kong, D. Thompson, S. M. Pitson, S. Pyne, and N. J. Pyne Sphingosine 1-Phosphate and Platelet-derived Growth Factor (PDGF) Act via PDGFbeta Receptor-Sphingosine 1-Phosphate Receptor Complexes in Airway Smooth Muscle Cells J. Biol. Chem., February 14, 2003; 278(8): 6282 - 6290. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Goel, P. J. Phillips-Mason, D. M. Raben, and J. J. Baldassare alpha -Thrombin Induces Rapid and Sustained Akt Phosphorylation by beta -Arrestin1-dependent and -independent Mechanisms, and Only the Sustained Akt Phosphorylation Is Essential for G1 Phase Progression J. Biol. Chem., May 17, 2002; 277(21): 18640 - 18648. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. MacInnis and R. B. Campenot Retrograde Support of Neuronal Survival Without Retrograde Transport of Nerve Growth Factor Science, February 22, 2002; 295(5559): 1536 - 1539. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Alderton, S. Rakhit, K. C. Kong, T. Palmer, B. Sambi, S. Pyne, and N. J. Pyne Tethering of the Platelet-derived Growth Factor beta Receptor to G-protein-coupled Receptors. A NOVEL PLATFORM FOR INTEGRATIVE SIGNALING BY THESE RECEPTOR CLASSES IN MAMMALIAN CELLS J. Biol. Chem., July 20, 2001; 276(30): 28578 - 28585. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. F. Wan, B. S. Sambi, M. Frame, R. Tate, and N. J. Pyne The Inhibitory gamma Subunit of the Type 6 Retinal Cyclic Guanosine Monophosphate Phosphodiesterase Is a Novel Intermediate Regulating p42/p44 Mitogen-activated Protein Kinase Signaling in Human Embryonic Kidney 293 Cells J. Biol. Chem., October 5, 2001; 276(41): 37802 - 37808. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||